🔥 Korea's Biotech Industry Leap! Comprehensive Analysis of SK Bioscience Vaccine Development and US Tariff Impact
📅 Analysis Period: May 5, 2025 - May 6, 2025
📌 SK Bioscience Partners with Government to Develop Next-Generation Avian Influenza Vaccine
SK Bioscience has begun working with the Korea Disease Control and Prevention Agency (KDCA) to develop an avian influenza vaccine as part of efforts to build a national defense system against future pandemics. The project, with an initial development budget of approximately 5.25 billion won, will leverage SK Bioscience's experience in commercializing vaccines using cell culture technology to strengthen the country's infectious disease response capabilities.
- SK Bioscience Launches Avian Influenza Vaccine Development... "Preparing for Outbreaks"
• Selected for KDCA's "Rapid Development Technology Support Project for Priority Infectious Disease Pandemic Preparedness"
• Article Link | 2025.05.06 - SK Bioscience-KDCA Embarks on Avian Influenza Vaccine Development... National Defense System Cooperation
• Launching national vaccine development project to prepare for next pandemic
• Article Link | 2025.05.06 - SK Bioscience Develops Next-Generation Avian Influenza Vaccine
• Applying new vaccine platform based on cell culture technology
• Article Link | 2025.05.06 - SK Bioscience and KDCA Begin Avian Influenza Vaccine Development
• Planning to invest approximately 5.25 billion won in development
• Article Link | 2025.05.06 - SK Bioscience Partners with KDCA to Develop Avian Influenza Vaccine
• Korea's only company to commercialize influenza vaccines using cell culture technology
• Article Link | 2025.05.06
📌 Pharmaceutical and Biotech Industries on Alert Following Trump's Tariff Announcement
Korean pharmaceutical and biotech companies are concerned as U.S. President Donald Trump has announced plans to reveal item-specific tariffs on pharmaceutical products within two weeks. In 2024, the U.S. imported pharmaceuticals worth $3.97 billion from Korea, and the industry is now exploring various countermeasures including local production options.
- "Here It Comes"... Pharma-Biotech Industry on High Alert After Trump's Tariff Warning
• President Trump signals major pharmaceutical pricing announcement next week
• Article Link | 2025.05.06 - "It Has Arrived"... Pharmaceutical-Biotech Industry Scrambles to Address Trump's Drug Tariffs
• Concerns over impact on $3.97 billion in pharmaceutical exports to U.S.
• Article Link | 2025.05.06 - Pharmaceutical-Biotech Industry Responding to Trump's Drug Tariffs with Local Production Options
• Companies expanding manufacturing facilities in the U.S.
• Article Link | 2025.05.06 - U.S., Korea's Largest Pharmaceutical Export Market, Announces Tariffs... "Will K-Biotech Face Greater Uncertainty?"
• Concerns about impact on pharmaceutical and biotech exports
• Article Link | 2025.05.06 - US-China 'Tariff War' Continues... K-Biotech Plays Cautious Game
• Increasing pressure on Big Pharma to relocate production facilities
• Article Link | 2025.05.06
📌 Bio Korea 2025 Convention Featuring 24 Startup Participants
The 'Bio Korea 2025' convention will be held at COEX in Seoul from May 7 to 9, with 24 biotech startups supported by the Ministry of SMEs and Startups in attendance. Hosted by the Korea Health Industry Development Institute and North Chungcheong Province, the event will provide opportunities for exchange with the global biotech ecosystem and investment attraction.
- 24 Advanced Startups Supported by Ministry of SMEs to Participate in 'Bio Korea 2025'
• Event to be held at COEX in Seoul on May 7-9
• Article Link | 2025.05.06 - Advanced Startups Expanding Globally... Heading to Bio Korea
• Opportunity to network with global investors
• Article Link | 2025.05.06 - Ministry's '1000+ Project' Startups to Participate in 'Bio Korea 2025'
• Supporting companies with advanced technological capabilities
• Article Link | 2025.05.06 - Advanced Startups Participating in 'Bio Korea 2025' in Large Numbers
• Opportunity to showcase technology and engage in international networking
• Article Link | 2025.05.06 - 'Bio Korea 2025' Opens: "Presenting the Direction of Future Health Industry"
• Co-hosted by Ministry of Health and Welfare and Korea Health Industry Development Institute
• Article Link | 2025.05.06
📌 Global Biotech Market Trends and Corporate Activities
Korean biotech companies are strengthening their global competitiveness, particularly in the U.S. market. Biovizion has successfully completed demand forecasting for its KOSDAQ listing, while companies like Tium Bio and Lunit are expected to present notable clinical data at ASCO. Additionally, Organoid Science has recorded the highest offering price among biotech companies this year.
- Biovizion's Demand Forecast 'Success'... Over 2,400 Institutions Participating
• Confirmed offering price at the upper end of the band during KOSDAQ listing process
• Article Link | 2025.05.06 - K-Biotech Companies Gaining Attention at ASCO... Which KOSDAQ Prospects?
• Focus on Tium Bio, Lunit, and Immunoncia
• Article Link | 2025.05.06 - U.S. FDA Animal Testing Elimination News Leads to Record Biotech Offering Price
• Organoid Science records highest offering price among biotech companies this year
• Article Link | 2025.05.06 - "We Want to Learn About K-Beauty"... Middle Eastern Medical Staff Learn Plastic Surgery Techniques
• CGBIO hosts academy for Middle Eastern medical professionals
• Article Link | 2025.05.05 - U.S. Tariff Announcement to Inevitably Impact K-Biotech 'Emergency Response'
• Celltrion, SK Bio and others preparing local production alternatives
• Article Link | 2025.05.06
📌 Domestic Biotech Industry Development and Policy Trends
The Korean government is implementing various policies to establish a national defense system and foster the biotech industry. The KDCA supports vaccine development through the 'Rapid Development Technology Support Project for Priority Infectious Disease Pandemic Preparedness,' while the Ministry of SMEs and Startups helps biotech startups grow through the '1000+ Project.'
- SK Bioscience-KDCA Begin Avian Influenza Vaccine Development... "Pandemic Preparedness"
• Establishing cooperation system for national defense
• Article Link | 2025.05.06 - SK Bioscience to Develop 'Avian Influenza Vaccine' as National Project
• Strengthening domestic vaccine development capabilities based on cell culture technology
• Article Link | 2025.05.06 - 24 Advanced Startups Issue Challenge at 'Bio Korea 2025' Stage
• Accelerating global expansion with Ministry of SMEs support
• Article Link | 2025.05.06 - "Made in USA Pharmaceuticals" Signal... Korean Pharma-Biotech Also in Tariff Storm Zone
• Need for domestic industry response to U.S. production promotion policies
• Article Link | 2025.05.06 - SK Bioscience and KDCA Launch 'Avian Influenza Vaccine' Development... "Preparing for Next Pandemic"
• Securing vaccine sovereignty through rapid development technology
• Article Link | 2025.05.06
📈 AI-Based Stock Recommendations
| Company | Recommendation Reason |
|---|---|
| SK Bioscience | Recognition of vaccine technology and stable revenue expected through government collaboration on avian influenza vaccine development |
| Celltrion | Long-term competitiveness expected due to plans to strengthen local production in response to U.S. tariffs |
| Tium Bio | Expected to highlight technological capabilities with notable clinical data presentation at ASCO |
| Lunit | Leading company in AI medical technology with expanding global recognition |
| Biovizion | High growth potential indicated by KOSDAQ listing progress and strong interest from institutional investors |
🔑 Key Keywords
SK Bioscience, Avian Influenza Vaccine, Trump Tariffs, Bio Korea 2025, Advanced Startups, K-Biotech, Pandemic Preparedness, Cell Culture Technology, Local Production, Korea Disease Control Agency
